Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Prime Time for Lower Extremity Artery Disease

Author(s): Marco De Carlo

Volume 18, Issue 3, 2020

Page: [201 - 203] Pages: 3

DOI: 10.2174/1570161117999190724145226

Next »
[1]
Aboyans V, Braekkan S, Mazzolai L, Sillesen H, Venermo M, De Carlo M. ESC Working Group on Aorta and Peripheral Vascular Diseases. The year 2017 in cardiology: aorta and peripheral circulation. Eur Heart J 2018; 39(9): 730-8.
[http://dx.doi.org/10.1093/eurheartj/ehx800] [PMID: 29300868]
[2]
Mukherjee D, Eagle K. The importance of early diagnosis and treatment in peripheral arterial disease: insights from the PARTNERS and REACH registries. Curr Vasc Pharmacol 2010; 8(3): 293-300.
[http://dx.doi.org/10.2174/157016110791112304] [PMID: 19758116]
[3]
Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015; 116(9): 1509-26.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.303849] [PMID: 25908725]
[4]
Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016; 67(23): 2719-28.
[http://dx.doi.org/10.1016/j.jacc.2016.03.524] [PMID: 27046162]
[5]
Bonaca MP, Gutierrez JA, Creager MA, et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: Results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (TRA2P-TIMI 50). Circulation 2016; 133(10): 997-1005.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.019355] [PMID: 26826179]
[6]
Jones WS, Baumgartner I, Hiatt WR, et al. International Steering Committee and Investigators of the EUCLID Trial. Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation 2017; 135(3): 241-50.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025880] [PMID: 27840336]
[7]
Sigvant B, Kragsterman B, Falkenberg M, et al. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. J Vasc Surg 2016; 64(4): 1009-17.
[http://dx.doi.org/10.1016/j.jvs.2016.03.429] [PMID: 27209402]
[8]
Bhatt DL, Steg PG, Ohman EM, et al. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295(2): 180-9.
[http://dx.doi.org/10.1001/jama.295.2.180] [PMID: 16403930]
[9]
Gallino A, Aboyans V, Diehm C, et al. European Society of Cardiology Working Group on Peripheral Circulation. Non-coronary atherosclerosis. Eur Heart J 2014; 35(17): 1112-9.
[http://dx.doi.org/10.1093/eurheartj/ehu071] [PMID: 24595865]
[10]
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348(9038): 1329-39.
[http://dx.doi.org/10.1016/S0140-6736(96)09457-3] [PMID: 8918275]
[11]
Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354(16): 1706-17.
[http://dx.doi.org/10.1056/NEJMoa060989] [PMID: 16531616]
[12]
Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2degreesP-TIMI 50. Circulation 2013; 127(14): 1522-29.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.000679] [PMID: 23501976]
[13]
Hiatt WR, Fowkes FG, Heizer G, et al. EUCLID Trial Steering Committee and Investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017; 376(1): 32-40.
[http://dx.doi.org/10.1056/NEJMoa1611688] [PMID: 27959717]
[14]
Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with pcsk9 inhibition in subjects with elevated risk). Circulation 2018; 137(4): 338-50.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032235] [PMID: 29133605]
[15]
Tendera M, Aboyans V, Bartelink ML, et al. uropean stroke organisation; ESC committee for practice guidelines. ESC guidelines on the diagnosis and treatment of peripheral artery diseases. Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32(22): 2851-906.
[http://dx.doi.org/10.1093/eurheartj/ehr211] [PMID: 21873417]
[16]
Aboyans V, Ricco JB, Bartelink MEL, et al. ESC Scientific Document Group. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J 2018; 39(9): 763-816.
[http://dx.doi.org/10.1093/eurheartj/ehx095] [PMID: 28886620]
[17]
Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377(14): 1319-30.
[http://dx.doi.org/10.1056/NEJMoa1709118] [PMID: 28844192]
[18]
Anand SS, Bosch J, Eikelboom JW, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391(10117): 219-29.
[http://dx.doi.org/10.1016/S0140-6736(17)32409-1] [PMID: 29132880]
[19]
De Carlo M. Cost-effectiveness analysis: A tool in the hands of the clinician. Eur J Prev Cardiol 2019; 26(8): 855-7.
[http://dx.doi.org/10.1177/2047487318822357] [PMID: 30861695]
[20]
Zomer E, Si S, Hird TR, et al. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. Eur J Prev Cardiol 2019; 26(8): 858-68.
[http://dx.doi.org/10.1177/2047487318817910] [PMID: 30526023]
[21]
Ademi Z, Zomer E, Tonkin A, Liew D. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. Int J Cardiol 2018; 270: 54-9.
[http://dx.doi.org/10.1016/j.ijcard.2018.06.091] [PMID: 30220379]
[22]
Jones WS, Mi X, Qualls LG, et al. Trends in settings for peripheral vascular intervention and the effect of changes in the outpatient prospective payment system. J Am Coll Cardiol 2015; 65(9): 920-7.
[http://dx.doi.org/10.1016/j.jacc.2014.12.048] [PMID: 25744009]
[23]
De Carlo M, Aboyans V. The re-birth of an ESC Working Group. Eur Heart J 2018; 39(9): 725-6.
[http://dx.doi.org/10.1093/eurheartj/ehy047] [PMID: 29506065]
[24]
Cea-Soriano L, Fowkes FGR, Johansson S, Allum AM, García Rodriguez LA. Time trends in peripheral artery disease incidence, prevalence and secondary preventive therapy: a cohort study in The Health Improvement Network in the UK. BMJ Open 2018; 8(1) e018184
[http://dx.doi.org/10.1136/bmjopen-2017-018184] [PMID: 29358428]
[25]
Habib A, Petrucci G, Rocca B. Pathophysiology of thrombosis in peripheral artery disease. Curr Vasc Pharmacol 2020; 18: 204-14.
[PMID: 30727897]
[26]
Vrsalovic M, Aboyans V. Antithrombotic therapy in lower extremity artery disease. Curr Vasc Pharmacol 2020; 18: 215-22.
[PMID: 30727898]
[27]
De Carlo M, Angelillis M, Liga R. Antithrombotic therapy for peripheral revascularization. Curr Vasc Pharmacol 2020; 18: 223-35.
[PMID: 30727899]
[28]
Alatri A, Mazzolai L. The bleeding risk in antithrombotic therapies: a narrative review. Curr Vasc Pharmacol 2020; 18: 236-47.
[http://dx.doi.org/10.2174/1570161117666190212112743] [PMID: 30747072]

Rights & Permissions Print Cite
Article Metrics
25
6
1
1
© 2024 Bentham Science Publishers | Privacy Policy